BioXcel Therapeutics Inc - BTAI Enterprise Value-to-Sales Ratio

Public company logo of BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics (BTAI) is betting on the digital transformation of neuropsychiatric medicines through AI. The company's price-to-sales trend reflects the dynamics of this course, where 125621.62 records a new level. Stable raw material supplies guarantee uninterrupted production, while the expansion of the drug Igalmi and new licenses in the US create a powerful impulse for sales growth.

BioXcel Therapeutics Corp (BTAI): EV/Sales Multiple from 11/23/2025 to 09/19/2026

BTAI (bioxceltherapeutics.com): analytical breakdowns and indicator data

Fundamental valuation:BioXcel Therapeutics, BTAI
Original product of BioXcel Therapeutics

For BioXcel Therapeutics (BTAI), which monetizes psychiatric disorder treatments, this indicator compares enterprise value with sales volume, eliminating distortions from debt load and cost inflation. By analyzing the EV-to-revenue trend, an investor assesses the market consensus regarding the business's operational efficiency, where a declining ratio may signal a risk of margin compression while asset value remains constant.